**Purpose:** A comparison of rivaroxaban to placebo in high-risk patients for prevention of post-discharge venous thromboembolism (VTE) events and death.

**Trial Design:** Phase 3, randomized 1:1, double-blinded, placebo-controlled trial. Patients treated for 45 days after discharge and followed for 30 days. Rivaroxaban 7.5 mg or 10 mg daily (based on creatinine clearance) or placebo. N=12,019.

**Primary Endpoints:**
- **Efficacy:** Time to first occurrence of symptomatic VTE events and VTE-related death; days 1-45.
- **Safety:** Major bleeding

**Secondary:** non-fatal VTE

<table>
<thead>
<tr>
<th></th>
<th>Symptomatic VTE, VTE-related death P=0.136</th>
<th>Major Bleeding P=0.124</th>
<th>Non-fatal VTE P=0.033</th>
</tr>
</thead>
<tbody>
<tr>
<td>placebo</td>
<td>1.10%</td>
<td>0.15%</td>
<td>0.42%</td>
</tr>
<tr>
<td>rivaroxaban</td>
<td>0.83%</td>
<td>0.28%</td>
<td>0.18%</td>
</tr>
</tbody>
</table>

**Results:** The risk for symptomatic VTE or of VTE-related death wasn’t significantly lower with rivaroxaban compared to placebo when given for 45 days after discharge.